nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Angioedema—Everolimus—kidney cancer	0.00237	0.00237	CcSEcCtD
Oritavancin—Erythema multiforme—Sunitinib—kidney cancer	0.00236	0.00236	CcSEcCtD
Oritavancin—Immune system disorder—Sorafenib—kidney cancer	0.00234	0.00234	CcSEcCtD
Oritavancin—Mediastinal disorder—Sorafenib—kidney cancer	0.00233	0.00233	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Pazopanib—kidney cancer	0.00232	0.00232	CcSEcCtD
Oritavancin—Cardiac disorder—Sunitinib—kidney cancer	0.00231	0.00231	CcSEcCtD
Oritavancin—Malnutrition—Sorafenib—kidney cancer	0.00225	0.00225	CcSEcCtD
Oritavancin—Immune system disorder—Sunitinib—kidney cancer	0.00225	0.00225	CcSEcCtD
Oritavancin—Mediastinal disorder—Sunitinib—kidney cancer	0.00224	0.00224	CcSEcCtD
Oritavancin—Erythema multiforme—Dactinomycin—kidney cancer	0.00223	0.00223	CcSEcCtD
Oritavancin—Abscess—Doxorubicin—kidney cancer	0.00223	0.00223	CcSEcCtD
Oritavancin—Myalgia—Everolimus—kidney cancer	0.00221	0.00221	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.00219	0.00219	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Paclitaxel—kidney cancer	0.00218	0.00218	CcSEcCtD
Oritavancin—Malnutrition—Sunitinib—kidney cancer	0.00217	0.00217	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Paclitaxel—kidney cancer	0.00213	0.00213	CcSEcCtD
Oritavancin—Myalgia—Erlotinib—kidney cancer	0.00213	0.00213	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.00212	0.00212	CcSEcCtD
Oritavancin—Infection—Everolimus—kidney cancer	0.0021	0.0021	CcSEcCtD
Oritavancin—Hypersensitivity—Temsirolimus—kidney cancer	0.0021	0.0021	CcSEcCtD
Oritavancin—Anaemia—Sorafenib—kidney cancer	0.00208	0.00208	CcSEcCtD
Oritavancin—Nervous system disorder—Everolimus—kidney cancer	0.00208	0.00208	CcSEcCtD
Oritavancin—Connective tissue disorder—Vincristine—kidney cancer	0.00207	0.00207	CcSEcCtD
Oritavancin—Tachycardia—Everolimus—kidney cancer	0.00207	0.00207	CcSEcCtD
Oritavancin—Angioedema—Sorafenib—kidney cancer	0.00206	0.00206	CcSEcCtD
Oritavancin—Skin disorder—Everolimus—kidney cancer	0.00206	0.00206	CcSEcCtD
Oritavancin—Infection—Erlotinib—kidney cancer	0.00203	0.00203	CcSEcCtD
Oritavancin—Extravasation—Doxorubicin—kidney cancer	0.00202	0.00202	CcSEcCtD
Oritavancin—Pruritus—Temsirolimus—kidney cancer	0.00202	0.00202	CcSEcCtD
Oritavancin—Nervous system disorder—Erlotinib—kidney cancer	0.002	0.002	CcSEcCtD
Oritavancin—Anaemia—Sunitinib—kidney cancer	0.002	0.002	CcSEcCtD
Oritavancin—Skin disorder—Erlotinib—kidney cancer	0.00199	0.00199	CcSEcCtD
Oritavancin—Angioedema—Sunitinib—kidney cancer	0.00198	0.00198	CcSEcCtD
Oritavancin—Oedema peripheral—Gemcitabine—kidney cancer	0.00197	0.00197	CcSEcCtD
Oritavancin—Connective tissue disorder—Gemcitabine—kidney cancer	0.00196	0.00196	CcSEcCtD
Oritavancin—Cardiac disorder—Vincristine—kidney cancer	0.00196	0.00196	CcSEcCtD
Oritavancin—Diarrhoea—Temsirolimus—kidney cancer	0.00195	0.00195	CcSEcCtD
Oritavancin—Cellulitis—Doxorubicin—kidney cancer	0.00194	0.00194	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Everolimus—kidney cancer	0.00193	0.00193	CcSEcCtD
Oritavancin—Myalgia—Sorafenib—kidney cancer	0.00192	0.00192	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.00191	0.00191	CcSEcCtD
Oritavancin—Hyperuricaemia—Doxorubicin—kidney cancer	0.0019	0.0019	CcSEcCtD
Oritavancin—Mediastinal disorder—Vincristine—kidney cancer	0.0019	0.0019	CcSEcCtD
Oritavancin—Pruritus—Pazopanib—kidney cancer	0.0019	0.0019	CcSEcCtD
Oritavancin—Anaemia—Dactinomycin—kidney cancer	0.0019	0.0019	CcSEcCtD
Oritavancin—Erythema multiforme—Gemcitabine—kidney cancer	0.00189	0.00189	CcSEcCtD
Oritavancin—Dizziness—Temsirolimus—kidney cancer	0.00188	0.00188	CcSEcCtD
Oritavancin—Infestation NOS—Paclitaxel—kidney cancer	0.00186	0.00186	CcSEcCtD
Oritavancin—Infestation—Paclitaxel—kidney cancer	0.00186	0.00186	CcSEcCtD
Oritavancin—Blood bilirubin increased—Doxorubicin—kidney cancer	0.00186	0.00186	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Erlotinib—kidney cancer	0.00186	0.00186	CcSEcCtD
Oritavancin—Cardiac disorder—Gemcitabine—kidney cancer	0.00185	0.00185	CcSEcCtD
Oritavancin—Myalgia—Sunitinib—kidney cancer	0.00185	0.00185	CcSEcCtD
Oritavancin—Diarrhoea—Pazopanib—kidney cancer	0.00184	0.00184	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.00183	0.00183	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Everolimus—kidney cancer	0.00183	0.00183	CcSEcCtD
Oritavancin—Infection—Sorafenib—kidney cancer	0.00183	0.00183	CcSEcCtD
Oritavancin—Vomiting—Temsirolimus—kidney cancer	0.00181	0.00181	CcSEcCtD
Oritavancin—Immune system disorder—Gemcitabine—kidney cancer	0.00181	0.00181	CcSEcCtD
Oritavancin—Nervous system disorder—Sorafenib—kidney cancer	0.0018	0.0018	CcSEcCtD
Oritavancin—Mediastinal disorder—Gemcitabine—kidney cancer	0.0018	0.0018	CcSEcCtD
Oritavancin—Rash—Temsirolimus—kidney cancer	0.0018	0.0018	CcSEcCtD
Oritavancin—Blood uric acid increased—Doxorubicin—kidney cancer	0.00179	0.00179	CcSEcCtD
Oritavancin—Dermatitis—Temsirolimus—kidney cancer	0.00179	0.00179	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Capecitabine—kidney cancer	0.00179	0.00179	CcSEcCtD
Oritavancin—Skin disorder—Sorafenib—kidney cancer	0.00179	0.00179	CcSEcCtD
Oritavancin—Headache—Temsirolimus—kidney cancer	0.00178	0.00178	CcSEcCtD
Oritavancin—Dizziness—Pazopanib—kidney cancer	0.00177	0.00177	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Erlotinib—kidney cancer	0.00176	0.00176	CcSEcCtD
Oritavancin—Infection—Sunitinib—kidney cancer	0.00176	0.00176	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Capecitabine—kidney cancer	0.00175	0.00175	CcSEcCtD
Oritavancin—Myalgia—Dactinomycin—kidney cancer	0.00175	0.00175	CcSEcCtD
Oritavancin—Nervous system disorder—Sunitinib—kidney cancer	0.00174	0.00174	CcSEcCtD
Oritavancin—Skin disorder—Sunitinib—kidney cancer	0.00172	0.00172	CcSEcCtD
Oritavancin—Vomiting—Pazopanib—kidney cancer	0.00171	0.00171	CcSEcCtD
Oritavancin—Anaemia—Vincristine—kidney cancer	0.0017	0.0017	CcSEcCtD
Oritavancin—Rash—Pazopanib—kidney cancer	0.00169	0.00169	CcSEcCtD
Oritavancin—Nausea—Temsirolimus—kidney cancer	0.00169	0.00169	CcSEcCtD
Oritavancin—Dermatitis—Pazopanib—kidney cancer	0.00169	0.00169	CcSEcCtD
Oritavancin—Bronchospasm—Capecitabine—kidney cancer	0.00169	0.00169	CcSEcCtD
Oritavancin—Headache—Pazopanib—kidney cancer	0.00168	0.00168	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.00168	0.00168	CcSEcCtD
Oritavancin—Infection—Dactinomycin—kidney cancer	0.00166	0.00166	CcSEcCtD
Oritavancin—Oedema peripheral—Paclitaxel—kidney cancer	0.00165	0.00165	CcSEcCtD
Oritavancin—Connective tissue disorder—Paclitaxel—kidney cancer	0.00164	0.00164	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.00161	0.00161	CcSEcCtD
Oritavancin—Anaemia—Gemcitabine—kidney cancer	0.00161	0.00161	CcSEcCtD
Oritavancin—Nausea—Pazopanib—kidney cancer	0.00159	0.00159	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Sorafenib—kidney cancer	0.00159	0.00159	CcSEcCtD
Oritavancin—Erythema multiforme—Paclitaxel—kidney cancer	0.00158	0.00158	CcSEcCtD
Oritavancin—Hypersensitivity—Vinblastine—kidney cancer	0.00157	0.00157	CcSEcCtD
Oritavancin—Myalgia—Vincristine—kidney cancer	0.00156	0.00156	CcSEcCtD
Oritavancin—Hypersensitivity—Everolimus—kidney cancer	0.00156	0.00156	CcSEcCtD
Oritavancin—Cardiac disorder—Paclitaxel—kidney cancer	0.00155	0.00155	CcSEcCtD
Oritavancin—Infestation NOS—Capecitabine—kidney cancer	0.00153	0.00153	CcSEcCtD
Oritavancin—Infestation—Capecitabine—kidney cancer	0.00153	0.00153	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Sunitinib—kidney cancer	0.00153	0.00153	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.00153	0.00153	CcSEcCtD
Oritavancin—Immune system disorder—Paclitaxel—kidney cancer	0.00151	0.00151	CcSEcCtD
Oritavancin—Mediastinal disorder—Paclitaxel—kidney cancer	0.00151	0.00151	CcSEcCtD
Oritavancin—Pruritus—Everolimus—kidney cancer	0.0015	0.0015	CcSEcCtD
Oritavancin—Infection—Vincristine—kidney cancer	0.00149	0.00149	CcSEcCtD
Oritavancin—Myalgia—Gemcitabine—kidney cancer	0.00148	0.00148	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.00147	0.00147	CcSEcCtD
Oritavancin—Nervous system disorder—Vincristine—kidney cancer	0.00147	0.00147	CcSEcCtD
Oritavancin—Urticaria—Sorafenib—kidney cancer	0.00146	0.00146	CcSEcCtD
Oritavancin—Malnutrition—Paclitaxel—kidney cancer	0.00146	0.00146	CcSEcCtD
Oritavancin—Diarrhoea—Vinblastine—kidney cancer	0.00146	0.00146	CcSEcCtD
Oritavancin—Diarrhoea—Everolimus—kidney cancer	0.00145	0.00145	CcSEcCtD
Oritavancin—Pruritus—Erlotinib—kidney cancer	0.00145	0.00145	CcSEcCtD
Oritavancin—Infection—Gemcitabine—kidney cancer	0.00141	0.00141	CcSEcCtD
Oritavancin—Dizziness—Vinblastine—kidney cancer	0.00141	0.00141	CcSEcCtD
Oritavancin—Dizziness—Everolimus—kidney cancer	0.0014	0.0014	CcSEcCtD
Oritavancin—Diarrhoea—Erlotinib—kidney cancer	0.0014	0.0014	CcSEcCtD
Oritavancin—Nervous system disorder—Gemcitabine—kidney cancer	0.00139	0.00139	CcSEcCtD
Oritavancin—Skin disorder—Gemcitabine—kidney cancer	0.00138	0.00138	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Vincristine—kidney cancer	0.00136	0.00136	CcSEcCtD
Oritavancin—Hypersensitivity—Sorafenib—kidney cancer	0.00135	0.00135	CcSEcCtD
Oritavancin—Oedema peripheral—Capecitabine—kidney cancer	0.00135	0.00135	CcSEcCtD
Oritavancin—Vomiting—Vinblastine—kidney cancer	0.00135	0.00135	CcSEcCtD
Oritavancin—Dizziness—Erlotinib—kidney cancer	0.00135	0.00135	CcSEcCtD
Oritavancin—Connective tissue disorder—Capecitabine—kidney cancer	0.00135	0.00135	CcSEcCtD
Oritavancin—Vomiting—Everolimus—kidney cancer	0.00135	0.00135	CcSEcCtD
Oritavancin—Anaemia—Paclitaxel—kidney cancer	0.00135	0.00135	CcSEcCtD
Oritavancin—Rash—Everolimus—kidney cancer	0.00134	0.00134	CcSEcCtD
Oritavancin—Dermatitis—Everolimus—kidney cancer	0.00133	0.00133	CcSEcCtD
Oritavancin—Headache—Vinblastine—kidney cancer	0.00133	0.00133	CcSEcCtD
Oritavancin—Angioedema—Paclitaxel—kidney cancer	0.00133	0.00133	CcSEcCtD
Oritavancin—Headache—Everolimus—kidney cancer	0.00133	0.00133	CcSEcCtD
Oritavancin—Hypoglycaemia—Doxorubicin—kidney cancer	0.00131	0.00131	CcSEcCtD
Oritavancin—Hypersensitivity—Sunitinib—kidney cancer	0.0013	0.0013	CcSEcCtD
Oritavancin—Pruritus—Sorafenib—kidney cancer	0.0013	0.0013	CcSEcCtD
Oritavancin—Vomiting—Erlotinib—kidney cancer	0.0013	0.0013	CcSEcCtD
Oritavancin—Erythema multiforme—Capecitabine—kidney cancer	0.0013	0.0013	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.00129	0.00129	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Vincristine—kidney cancer	0.00129	0.00129	CcSEcCtD
Oritavancin—Rash—Erlotinib—kidney cancer	0.00129	0.00129	CcSEcCtD
Oritavancin—Dermatitis—Erlotinib—kidney cancer	0.00129	0.00129	CcSEcCtD
Oritavancin—Headache—Erlotinib—kidney cancer	0.00128	0.00128	CcSEcCtD
Oritavancin—Cardiac disorder—Capecitabine—kidney cancer	0.00127	0.00127	CcSEcCtD
Oritavancin—Nausea—Vinblastine—kidney cancer	0.00126	0.00126	CcSEcCtD
Oritavancin—Nausea—Everolimus—kidney cancer	0.00126	0.00126	CcSEcCtD
Oritavancin—Diarrhoea—Sorafenib—kidney cancer	0.00126	0.00126	CcSEcCtD
Oritavancin—Pruritus—Sunitinib—kidney cancer	0.00125	0.00125	CcSEcCtD
Oritavancin—Immune system disorder—Capecitabine—kidney cancer	0.00124	0.00124	CcSEcCtD
Oritavancin—Myalgia—Paclitaxel—kidney cancer	0.00124	0.00124	CcSEcCtD
Oritavancin—Mediastinal disorder—Capecitabine—kidney cancer	0.00124	0.00124	CcSEcCtD
Oritavancin—Hypersensitivity—Dactinomycin—kidney cancer	0.00123	0.00123	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.00123	0.00123	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.00123	0.00123	CcSEcCtD
Oritavancin—Dizziness—Sorafenib—kidney cancer	0.00122	0.00122	CcSEcCtD
Oritavancin—Nausea—Erlotinib—kidney cancer	0.00121	0.00121	CcSEcCtD
Oritavancin—Diarrhoea—Sunitinib—kidney cancer	0.00121	0.00121	CcSEcCtD
Oritavancin—Malnutrition—Capecitabine—kidney cancer	0.0012	0.0012	CcSEcCtD
Oritavancin—Infection—Paclitaxel—kidney cancer	0.00118	0.00118	CcSEcCtD
Oritavancin—Dizziness—Sunitinib—kidney cancer	0.00117	0.00117	CcSEcCtD
Oritavancin—Vomiting—Sorafenib—kidney cancer	0.00117	0.00117	CcSEcCtD
Oritavancin—Nervous system disorder—Paclitaxel—kidney cancer	0.00117	0.00117	CcSEcCtD
Oritavancin—Tachycardia—Paclitaxel—kidney cancer	0.00116	0.00116	CcSEcCtD
Oritavancin—Rash—Sorafenib—kidney cancer	0.00116	0.00116	CcSEcCtD
Oritavancin—Dermatitis—Sorafenib—kidney cancer	0.00116	0.00116	CcSEcCtD
Oritavancin—Skin disorder—Paclitaxel—kidney cancer	0.00115	0.00115	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Doxorubicin—kidney cancer	0.00115	0.00115	CcSEcCtD
Oritavancin—Headache—Sorafenib—kidney cancer	0.00115	0.00115	CcSEcCtD
Oritavancin—Diarrhoea—Dactinomycin—kidney cancer	0.00115	0.00115	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Doxorubicin—kidney cancer	0.00113	0.00113	CcSEcCtD
Oritavancin—Vomiting—Sunitinib—kidney cancer	0.00113	0.00113	CcSEcCtD
Oritavancin—Rash—Sunitinib—kidney cancer	0.00112	0.00112	CcSEcCtD
Oritavancin—Dermatitis—Sunitinib—kidney cancer	0.00111	0.00111	CcSEcCtD
Oritavancin—Headache—Sunitinib—kidney cancer	0.00111	0.00111	CcSEcCtD
Oritavancin—Anaemia—Capecitabine—kidney cancer	0.0011	0.0011	CcSEcCtD
Oritavancin—Hypersensitivity—Vincristine—kidney cancer	0.0011	0.0011	CcSEcCtD
Oritavancin—Eosinophilia—Doxorubicin—kidney cancer	0.00109	0.00109	CcSEcCtD
Oritavancin—Nausea—Sorafenib—kidney cancer	0.00109	0.00109	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.00108	0.00108	CcSEcCtD
Oritavancin—Vomiting—Dactinomycin—kidney cancer	0.00107	0.00107	CcSEcCtD
Oritavancin—Rash—Dactinomycin—kidney cancer	0.00106	0.00106	CcSEcCtD
Oritavancin—Nausea—Sunitinib—kidney cancer	0.00105	0.00105	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.00103	0.00103	CcSEcCtD
Oritavancin—Diarrhoea—Vincristine—kidney cancer	0.00102	0.00102	CcSEcCtD
Oritavancin—Myalgia—Capecitabine—kidney cancer	0.00102	0.00102	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.00101	0.00101	CcSEcCtD
Oritavancin—Pruritus—Gemcitabine—kidney cancer	0.001	0.001	CcSEcCtD
Oritavancin—Nausea—Dactinomycin—kidney cancer	0.000995	0.000995	CcSEcCtD
Oritavancin—Dizziness—Vincristine—kidney cancer	0.00099	0.00099	CcSEcCtD
Oritavancin—Infestation—Doxorubicin—kidney cancer	0.000986	0.000986	CcSEcCtD
Oritavancin—Infestation NOS—Doxorubicin—kidney cancer	0.000986	0.000986	CcSEcCtD
Oritavancin—Diarrhoea—Gemcitabine—kidney cancer	0.000972	0.000972	CcSEcCtD
Oritavancin—Infection—Capecitabine—kidney cancer	0.000969	0.000969	CcSEcCtD
Oritavancin—Nervous system disorder—Capecitabine—kidney cancer	0.000957	0.000957	CcSEcCtD
Oritavancin—Tachycardia—Capecitabine—kidney cancer	0.000952	0.000952	CcSEcCtD
Oritavancin—Vomiting—Vincristine—kidney cancer	0.000952	0.000952	CcSEcCtD
Oritavancin—Skin disorder—Capecitabine—kidney cancer	0.000948	0.000948	CcSEcCtD
Oritavancin—Urticaria—Paclitaxel—kidney cancer	0.000944	0.000944	CcSEcCtD
Oritavancin—Rash—Vincristine—kidney cancer	0.000944	0.000944	CcSEcCtD
Oritavancin—Dermatitis—Vincristine—kidney cancer	0.000943	0.000943	CcSEcCtD
Oritavancin—Headache—Vincristine—kidney cancer	0.000938	0.000938	CcSEcCtD
Oritavancin—Vomiting—Gemcitabine—kidney cancer	0.000903	0.000903	CcSEcCtD
Oritavancin—Rash—Gemcitabine—kidney cancer	0.000895	0.000895	CcSEcCtD
Oritavancin—Dermatitis—Gemcitabine—kidney cancer	0.000894	0.000894	CcSEcCtD
Oritavancin—Headache—Gemcitabine—kidney cancer	0.00089	0.00089	CcSEcCtD
Oritavancin—Nausea—Vincristine—kidney cancer	0.000889	0.000889	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000889	0.000889	CcSEcCtD
Oritavancin—Hypersensitivity—Paclitaxel—kidney cancer	0.000876	0.000876	CcSEcCtD
Oritavancin—Oedema peripheral—Doxorubicin—kidney cancer	0.000872	0.000872	CcSEcCtD
Oritavancin—Connective tissue disorder—Doxorubicin—kidney cancer	0.00087	0.00087	CcSEcCtD
Oritavancin—Nausea—Gemcitabine—kidney cancer	0.000843	0.000843	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000842	0.000842	CcSEcCtD
Oritavancin—Pruritus—Paclitaxel—kidney cancer	0.000841	0.000841	CcSEcCtD
Oritavancin—Erythema multiforme—Doxorubicin—kidney cancer	0.000837	0.000837	CcSEcCtD
Oritavancin—Cardiac disorder—Doxorubicin—kidney cancer	0.000822	0.000822	CcSEcCtD
Oritavancin—Diarrhoea—Paclitaxel—kidney cancer	0.000813	0.000813	CcSEcCtD
Oritavancin—Immune system disorder—Doxorubicin—kidney cancer	0.0008	0.0008	CcSEcCtD
Oritavancin—Mediastinal disorder—Doxorubicin—kidney cancer	0.000798	0.000798	CcSEcCtD
Oritavancin—Dizziness—Paclitaxel—kidney cancer	0.000786	0.000786	CcSEcCtD
Oritavancin—Urticaria—Capecitabine—kidney cancer	0.000775	0.000775	CcSEcCtD
Oritavancin—Malnutrition—Doxorubicin—kidney cancer	0.000771	0.000771	CcSEcCtD
Oritavancin—Vomiting—Paclitaxel—kidney cancer	0.000756	0.000756	CcSEcCtD
Oritavancin—Rash—Paclitaxel—kidney cancer	0.00075	0.00075	CcSEcCtD
Oritavancin—Dermatitis—Paclitaxel—kidney cancer	0.000749	0.000749	CcSEcCtD
Oritavancin—Headache—Paclitaxel—kidney cancer	0.000745	0.000745	CcSEcCtD
Oritavancin—Hypersensitivity—Capecitabine—kidney cancer	0.000719	0.000719	CcSEcCtD
Oritavancin—Anaemia—Doxorubicin—kidney cancer	0.000712	0.000712	CcSEcCtD
Oritavancin—Nausea—Paclitaxel—kidney cancer	0.000706	0.000706	CcSEcCtD
Oritavancin—Pruritus—Capecitabine—kidney cancer	0.00069	0.00069	CcSEcCtD
Oritavancin—Diarrhoea—Capecitabine—kidney cancer	0.000668	0.000668	CcSEcCtD
Oritavancin—Myalgia—Doxorubicin—kidney cancer	0.000656	0.000656	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000652	0.000652	CcSEcCtD
Oritavancin—Dizziness—Capecitabine—kidney cancer	0.000645	0.000645	CcSEcCtD
Oritavancin—Infection—Doxorubicin—kidney cancer	0.000625	0.000625	CcSEcCtD
Oritavancin—Vomiting—Capecitabine—kidney cancer	0.00062	0.00062	CcSEcCtD
Oritavancin—Nervous system disorder—Doxorubicin—kidney cancer	0.000617	0.000617	CcSEcCtD
Oritavancin—Rash—Capecitabine—kidney cancer	0.000615	0.000615	CcSEcCtD
Oritavancin—Dermatitis—Capecitabine—kidney cancer	0.000615	0.000615	CcSEcCtD
Oritavancin—Tachycardia—Doxorubicin—kidney cancer	0.000614	0.000614	CcSEcCtD
Oritavancin—Headache—Capecitabine—kidney cancer	0.000611	0.000611	CcSEcCtD
Oritavancin—Skin disorder—Doxorubicin—kidney cancer	0.000611	0.000611	CcSEcCtD
Oritavancin—Nausea—Capecitabine—kidney cancer	0.000579	0.000579	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000573	0.000573	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000543	0.000543	CcSEcCtD
Oritavancin—Urticaria—Doxorubicin—kidney cancer	0.0005	0.0005	CcSEcCtD
Oritavancin—Hypersensitivity—Doxorubicin—kidney cancer	0.000463	0.000463	CcSEcCtD
Oritavancin—Pruritus—Doxorubicin—kidney cancer	0.000445	0.000445	CcSEcCtD
Oritavancin—Diarrhoea—Doxorubicin—kidney cancer	0.00043	0.00043	CcSEcCtD
Oritavancin—Dizziness—Doxorubicin—kidney cancer	0.000416	0.000416	CcSEcCtD
Oritavancin—Vomiting—Doxorubicin—kidney cancer	0.0004	0.0004	CcSEcCtD
Oritavancin—Rash—Doxorubicin—kidney cancer	0.000397	0.000397	CcSEcCtD
Oritavancin—Dermatitis—Doxorubicin—kidney cancer	0.000396	0.000396	CcSEcCtD
Oritavancin—Headache—Doxorubicin—kidney cancer	0.000394	0.000394	CcSEcCtD
Oritavancin—Nausea—Doxorubicin—kidney cancer	0.000374	0.000374	CcSEcCtD
